The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% ...

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

A Wall Street maxim states, “Twenty percent of investors who want to make money are in stocks, while the other 80 percent who ...

Top regulators like the US FDA and EMA are fast-tracking more Chinese drugs, granting priority review and breakthrough ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

HONG KONG] The biotechnology industry is experiencing a tectonic shift, driven by Chinese drugmakers who have come a long way ...

Glenmark Pharma’s licensing pact for its investigational cancer drug ISB 2001 is not just a deal --it’s a turning point in Indian pharma/biotech innovation. It reinforces the notion that India-based ...

With the rise of advanced simulation and model-informed drug development (MIDD) techniques like digital twins, researchers ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.